Nuwellis, Inc. (NASDAQ: NUWE) is engaged as a medical device company, which is focused on the development and commercialization of its Aquadex SmartFlow system for ultrafiltration therapy. Shares of the Minnesota-based company skyrocketed 121% during trading on Wednesday, August 31, 2022. Over the past three months, Nuwellis has seen average daily volume of 272,870 shares. However, volume of 134.09 million shares or dollar volume of around $195.77 million, exchanged hands during Wednesday’s trading session.
Shares of Nuwellis are soaring after the company released clinical data showing ultrafiltration therapy for high-risk post-operative coronary artery bypass grafting (CABG) surgery was a safe and effective method for managing fluids and reducing mortality. The key clinical data shows its Aquadex FlexFlow System demonstrated a 100% survival rate in the clinical research.
The study featured CABG patients that were receiving treatment at the Division of Cardiothoracic Surgery at Baylor scott & White Health in Temple, Texas between January 1, 2020 and July 31, 2021. During this period, 254 CABG procedures were performed at the medical facility. Ultrafiltration therapy was used in 17 patients. Although the patients did experience an elevated mean Society of Thoracic Surgeons mortality rate of 5.75. The survival rate of patients undergoing ultrafiltration was 100%.
“Ultrafiltration technology has been used for decades to successfully treat advanced heart failure patients and data hav been published to demonstrate its outcomes, but its application in cardiac surgery to treat fluid overload is innovative,” said Daniel Beckles, M.D., Surgical Director of Heart Transplantation and Mechanical Circulatory Support at Baylor Scott & White Health and the study’s lead author. “These favorable results are consistent with the clinical findings in other large academic centers using ultrafiltration technology in cardiac surgery, and we are eager to gather additional multi-institutional data about the use of Aquadex for this challenging patient population.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
